Release Date: 25 January 2025
TQB2102 is an antibody-drug conjugate (ADC) under development by Chia Tai Tianqing Pharmaceutical Group, a Chinese pharmaceutical company. This drug integrates a humanized monoclonal antibody that targets the tumor-associated antigen HER...
Release Date: 23 January 2025
China has emerged as a global leader in the research, development, and clinical trials of antibody-drug conjugates (ADCs), with over 400 ADCs currently in clinical trials across the country. This rapid growth has position...
Release Date: 23 January 2025
Ubamatamab (REGN4018) is a bispecific, human monoclonal antibody under investigation for its potential antineoplastic activity, particularly in the treatment of ovarian cancer. This innovative therapy has two antigen-reco...
Release Date: 23 January 2025
Obrixtamig (BI 764532) is an investigational bispecific antibody developed by Boehringer Ingelheim, designed to treat small cell lung cancer (SCLC) and other neuroendocrine neoplasms expressing the delta-like canonical No...
Release Date: 23 January 2025
BI 836880, developed by Boehringer Ingelheim, is a humanized bispecific nanobody designed to target two critical pathways involved in tumor growth and angiogenesis: vascular endothelial growth factor (VEGF) and angiopoiet...
Release Date: 23 January 2025
SI-B003 is an innovative bispecific, tetravalent antibody being developed by Sichuan Baili Pharmaceutical (Biokin Pharmaceutical) in China and SystImmune, a wholly owned subsidiary of Biokin in the United States. This pro...
Release Date: 23 January 2025
Acimtamig (AFM13) is a first-in-class ICEandreg; (innate cell engager) molecule developed by Affimed, designed to target CD30 on cancer cells and CD16A on innate immune cells. This innovative therapy aims to leverage the ...
Release Date: 23 January 2025
MEDI7352 is an innovative experimental drug developed by AstraZeneca, aimed at addressing chronic pain through a novel mechanism. Unlike traditional analgesics, it is a bispecific monoclonal antibody that targets two key ...
Release Date: 23 January 2025
Lutikizumab (ABT-981) is a dual-variable-domain interleukin (IL) 1andalpha;/1andbeta; antagonist developed by AbbVie, designed to target and neutralize two key inflammatory cytokines: IL-1andalpha; and IL-1andbeta;. These...
Release Date: 23 January 2025
Acasunlimab (GEN1046) is an investigational bispecific antibody developed using Genmab's DuoBodyandreg; technology platform, in collaboration with BioNTech. This first-in-class therapeutic agent targets two immune pathway...
Release Date: 23 January 2025
FS118 is a promising tetravalent bispecific antibody developed by F-star Therapeutics, a subsidiary of InvoX Pharma, designed to target two key immune checkpoints: lymphocyte-activation gene 3 (LAG-3) and programmed cell ...
Release Date: 23 January 2025
Lomvastomig (RO 7121661) is a bispecific antibody developed by Roche that targets two critical immune checkpoint receptors: programmed death-1 (PD-1) and T-cell immunoglobulin and mucin domain 3 (TIM-3). Both PD-1 and TIM...
Release Date: 23 January 2025
IBI322 is a promising bispecific antibody developed by Innovent Biologics, designed to target two key immunosuppressive pathways that tumors exploit to evade the immune system. It is a recombinant anti-human CD47/PD-L1 an...
Release Date: 23 January 2025
MAS825 is a bispecific monoclonal antibody developed by Novartis, designed to target two key pro-inflammatory cytokines, interleukin-1 beta (IL-1andbeta;) and interleukin-18 (IL-18). Both IL-1andbeta; and IL-18 play pivot...
Release Date: 23 January 2025
Maridebart cafraglutide, previously known as AMG 133, is an innovative antibody-peptide conjugate currently under development by Amgen to address obesity and potentially Type 2 diabetes mellitus. This promising therapeuti...